학술논문
A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial
Document Type
Article
Author
Source
In Gynecologic Oncology September 2015 138(3):513-518
Subject
Language
ISSN
0090-8258